Table 1

Association between corticofugal fibres and clinical outcome

	M1	PMdv	SMA
Arm>0	2.90 (1.41–5.99)	3.57 (1.38–9.24)	2.00 (1.09–3.68)	OR and 95% CI
	0.22	0.18	0.13	R²
	0.80 (0.66–0.94)	0.76 (0.61–0.91)	0.73 (0.58–0.88)	AUC and 95% CI
	0.96 (0.79, 0.82)	0.86 (0.74, 0.84)	0.99 (0.79, 0.79)	Threshold volume (mL) sensitivity and specificity
Leg>0	1.75 (1.05–2.94)	2.42 (1.09–5.40)	1.86 (1.06–3.28)	OR and 95% CI
	0.18	0.22	0.19	R²
	0.69 (0.52–0.85)	0.67 (0.50–0.85)	0.66 (0.48–0.84)	AUC and 95% CI
	1.06 (0.65, 0.75)	0.91 (0.59, 0.75)	0.99 (0.65, 0.70)	Threshold volume (mL) sensitivity and specificity
Modified Rankin>2	3.22 (1.48–6.97)	4.42 (1.41–13.84)	2.66 (1.29–5.50)	OR and 95% CI
	0.31	0.29	0.25	R²
	0.88 (0.79–0.97)	0.83 (0.70–0.97)	0.82 (0.67–0.97)	AUC and 95% CI
	1.05 (1.00, 0.77)	1.01 (0.80, 0.77)	1.00 (0.80, 0.74)	Threshold volume (mL) sensitivity and specificity

Different metrics of association between corticofugal fibres and outcome were presented for ease of comparison with other studies.
AUC, area under the receiver operating characteristics curve; M1, motor cortex; PMdv, dorsal and ventral premotor area; SMA, supplementary motor area.